Melanoma risk during immunomodulating treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Melanoma risk during immunomodulating treatment

Published:2022-08-22 Issue:6 Volume:32 Page:411-418
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Zheng Yixuan James,Ho Wilson,Sanlorenzo Martina,Vujic Igor,Daud Adil,Algazi Alain,Rappersberger Klemens,Ortiz-Urda Susana

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference86 articles.

1. Cancer immunoediting: from immunosurveillance to tumor escape.;Dunn;Nat Immunol,2002

2. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.;Quaglino;Ann Oncol,2010

3. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.;Atkins;Cancer J Sci Am,2000

4. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.;Di Giacomo;Cancer Immunol Immunother,2013

5. Non-melanoma skin cancer.;Madan;Lancet,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The benefit of sentinel lymph node biopsy in elderly patients with melanoma;The American Journal of Surgery;2024-11

2. Cogan-Like Syndrome Following Nivolumab Immunotherapy for Metastatic Cutaneous Melanoma;Ocular Immunology and Inflammation;2024-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP